Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluminate-5: Elecoglipron and dapagliflozin in adults with type 2 diabetes mellitus
jRCT2031260261Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of elecoglipron and dapagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in Hemoglobin A1c (HbA1c). Started Jul 2026; status: recruiting.
02
Drugs
elecogliprondapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031260261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260261.